# β-Asarone Mediates the Alleviation of Neuroinflammation in Alzheimer’s Disease Via Modulation of the TREM2/PI3K/AKT Signaling Pathway

**Authors:** Na Yang, Jiajun Jiang, Jianhong Shi, Xuan Liu, Chenshi Yu, Shunyuan Guo, Chengliang Zhang, Feng Gao, Zijian Yang, Huina Feng, Qiuyan Weng, Tao Qiu, Changyu Li, Liting Ji

PMC · DOI: 10.1007/s10753-025-02435-w · Inflammation · 2026-02-24

## TL;DR

β-asarone reduces neuroinflammation in Alzheimer’s disease by regulating microglial activity through a specific signaling pathway.

## Contribution

This study is the first to show that β-asarone alleviates AD pathology via the TREM2/PI3K/AKT/GSK3β signaling axis.

## Key findings

- β-asarone improved cognitive function and reduced hippocampal damage in 3×Tg-AD mice.
- The compound decreased Aβ deposition and Tau hyperphosphorylation in AD models.
- β-asarone promotes microglial polarization from M1 to M2 phenotypes via TREM2/PI3K/AKT signaling.

## Abstract

Neuroinflammation, driven by dysregulated microglial polarization, is a hallmark of Alzheimer’s disease (AD). Recently, the triggering receptor expressed on myeloid cells 2 (TREM2), a key regulator of microglial function, has emerged as a promising therapeutic target for AD. This study aimed to investigate the therapeutic potential and mechanism of action of the natural compound β-asarone in AD models. Our results demonstrate that β-asarone significantly improved cognitive function, reduced hippocampal neuronal damage, and decreased both Aβ deposition and Tau hyperphosphorylation in 3×Tg-AD mice. Mechanistically, β-asarone upregulated TREM2 expression, activated the PI3K/AKT pathway, and inhibited GSK3β activity, thereby promoting the polarization of microglia from the pro-inflammatory M1 phenotype toward the anti-inflammatory M2 phenotype and alleviating neuroinflammation. This study is the first to elucidate that β-asarone ameliorates AD pathology by modulating microglial polarization via the TREM2/PI3K/AKT/GSK3β signaling axis, providing experimental evidence supporting its potential as an immunomodulatory therapeutic agent for AD.

The online version contains supplementary material available at 10.1007/s10753-025-02435-w.

## Linked entities

- **Genes:** TREM2 (triggering receptor expressed on myeloid cells 2) [NCBI Gene 54209], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932]
- **Chemicals:** β-asarone (PubChem CID 17903)
- **Diseases:** Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Iba1 (induction of brown adipocytes 1) [NCBI Gene 114737], Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Trem2 (triggering receptor expressed on myeloid cells 2) [NCBI Gene 83433] {aka TREM-2, Trem2a, Trem2b, Trem2c}, Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, Gfap (glial fibrillary acidic protein) [NCBI Gene 14580], Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Blnk (B cell linker) [NCBI Gene 17060] {aka BASH, Bca, Ly-57, Ly57, Lyw-57, SLP-65}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Apoe (apolipoprotein E) [NCBI Gene 11816] {aka Apo-E}, Ppia (peptidylprolyl isomerase A) [NCBI Gene 268373] {aka Cphn, CyP-18, CypA, SP18}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Tyrobp (TYRO protein tyrosine kinase binding protein) [NCBI Gene 22177] {aka DAP12, KARAP, Ly83}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, H2-Ab1 (histocompatibility 2, class II antigen A, beta 1) [NCBI Gene 14961] {aka Abeta, H-2Ab, H2-Ab, I-Abeta, IAb, Ia-2}, Cxcl15 (C-X-C motif chemokine ligand 15) [NCBI Gene 20309] {aka Il8, Scyb15, lungkine, weche}, Gsk3b (glycogen synthase kinase 3 beta) [NCBI Gene 56637] {aka 7330414F15Rik, 8430431H08Rik, GSK-3, GSK-3beta, GSK3}, Syk (spleen tyrosine kinase) [NCBI Gene 20963] {aka Sykb}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}
- **Diseases:** inflammation (MESH:D007249), neurodegeneration (MESH:D019636), mitochondrial dysfunction (MESH:D028361), Parkinson's disease (MESH:D010300), neurotoxic (MESH:D020258), AD (MESH:D000544), Neuroinflammation (MESH:D000090862), neuronal damage (MESH:D009410), proinflammatory cytokines (MESH:D000080424), depression (MESH:D003866), learning and memory deficits (MESH:D007859), pathological damage (MESH:D005598), neuronal dysfunction (MESH:D009461), senile plaques (MESH:D058225), neuropathological injury (MESH:D009422), Cognitive Deficits (MESH:D003072), impaired spatial memory (MESH:D008569), NFTs (MESH:D055956)
- **Chemicals:** Paraffin (MESH:D010232), HE (-), metal (MESH:D008670), DNPZ (MESH:D000077265), sodium citrate (MESH:D000077559), Alexa Fluor 647 (MESH:C569686), hematoxylin (MESH:D006416), ammonia (MESH:D000641), penicillin (MESH:D010406), puromycin (MESH:D011691), xylene (MESH:D014992), Triton X-100 (MESH:D017830), Alexa Fluor 488 (MESH:C000711379), streptomycin (MESH:D013307), phospholipids (MESH:D010743), ATP (MESH:D000255), water (MESH:D014867), CCK-8 (MESH:D012844), CO2 (MESH:D002245), beta-Asarone (MESH:C012195), lipid (MESH:D008055), paraformaldehyde (MESH:C003043), LPS (MESH:D008070), STZ (MESH:D013311), essential oil (MESH:D009822), Tween-80 (MESH:D011136), eosin (MESH:D004801), hydrochloric acid (MESH:D006851), SDS (MESH:D012967), alcohol (MESH:D000438), PVDF (MESH:C024865), toluidine blue (MESH:D014048), DAPI (MESH:C007293), ethanol (MESH:D000431), glucose (MESH:D005947)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Acorus tatarinowii (species) [taxon 123564]
- **Mutations:** P13K, R47H
- **Cell lines:** BV2 — Mus musculus (Mouse), Transformed cell line (CVCL_0182)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960360/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960360/full.md

---
Source: https://tomesphere.com/paper/PMC12960360